{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040679","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.333990+00:00","generated_at":"2026-05-30T16:42:58.721481+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity appoints J. Michael Edwards as CFO; $300k salary, $50k bonus, 100k RSUs","bullets":["J. Michael Edwards appointed CFO effective Nov 5, 2024; annual base salary of $300,000.","Signing bonus: $50,000 cash and restricted stock award of 100,000 shares vesting 25% immediately, then over 3 years.","Edwards previously served as CFO from 2014-2023, oversaw 2022 IPO, and has been interim CFO since Sept 2024.","Employment agreement has one-year initial term, auto-renews annually; he reports to CEO Maria Zannes.","Company highlights Edwards' experience for commercialization of CyPath Lung, a noninvasive lung cancer test."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040679","json":"https://secwatch.observer/filing/0001493152-24-040679.json","markdown":"https://secwatch.observer/filing/0001493152-24-040679.md","text":"https://secwatch.observer/filing/0001493152-24-040679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/0001493152-24-040679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:42:58.721481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6118eb462e","claim":"J. Michael Edwards was appointed as Chief Financial Officer at bioAffinity Technologies, Inc..","evidence_excerpt":"On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/0001493152-24-040679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}